Comprehensive system that enables unmatched single cell multiomic analysis is now widely available following the completion of a successful Early Access Program
DURHAM, N.C. – February 7, 2023 - BioSkryb Genomics, a pioneer in comprehensive single cell multiomic research solutions, today announced t…
Suresh Pisharody brings strong leadership experience honed at Illumina, Thermo Fisher Scientific, and Guardant Health to lead BioSkryb in its next phase of growth
DURHAM, N.C. – January 31, 2023 - BioSkryb Genomics, a pioneer in comprehensive single-cell multi-omic research solutions, has appointed …
New partnership brings transformative, high-resolution single-cell genomic technology to the field of preimplantation genetic testing in the pursuit of improved discovery and clinical outcomes.
DURHAM, N.C., October 18, 2022 – BioSkryb Genomics, a pioneer in developing scientifically advanced single…
This new partnership brings high-resolution, single-cell whole genome and whole transcriptome analysis to Europe. This partnership will enable novel insights and deep cellular characterization required in the evaluation, creation, and validation of new generation biologics and therapeutics in target…
DURHAM, N.C., May 31, 2022--(BUSINESS WIRE)--BioSkryb Genomics, a biotech company developing advanced single-cell analysis tools, today announced the launch of the Early Access Program (EAP) for ResolveOME, a unified, single-cell workflow that amplifies the complete genome and full-length mRNA …
DURHAM, N.C.--(BUSINESS WIRE)--BioSkryb Genomics, a leader of single-cell genome amplification, and ALS Automated Lab Solutions GmbH, developers of a multi-patented spatial single cell and colony picking technology platform, today announced a U.S. distribution agreement to power comprehensive s…
Move supports company’s multi-year strategic growth initiative; advances retention, attraction, and expansion of the team; enhances the ability to serve customers; and demonstrates Company's commitment to the region
DURHAM, N.C., October 12, 2021 – BioSkryb Genomics, Inc., today announced the reloca…
We are excited to welcome three new team members who bring deep scientific knowledge as well as technical experience in supporting researcher needs in applying new genomic and molecular biology solutions.
“Just as we know each cell is unique, so are our people,” said Jay West, Ph.D., CEO and cofoun…
JULY 31 - HUATAI ZHI MADE (MGI), IDG INVESTMENT INNOVATION INSTITUTE AND BLUE RAINBOW LIFE SCIENCES ACCELERATOR JOINTLY ORGANIZED BY THE MGI & IDG CAPITAL ACCELERATED LIFE AND HEALTH BUSINESS (HEREINAFTER REFERRED TO AS "ACCELERATED CAMP") IN THE NANSHAN DISTRICT, SHENZHEN, IDG CAPITAL INNOVATION TH…
Dr. Harton to lead the translation of BioSkryb’s Primary Template-directed Amplification (PTA) technology into breakthrough diagnostic applications for targeted indications, including cancer and neurological disorders
DURHAM, N.C., June 30, 2021 -- BioSkryb, Inc., today announced the expansion of th…
